J. Goldman & Co’s Celldex Therapeutics CLDX Stock Holding History

J. Goldman & Co’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,300	Closed	-$513K	–	496
2024 Q4	$513K	Buy	+20,300	New	+$552K	0.01%	363
2024 Q3	–	Sell	-20,300	Closed	-$751K	–	487
2024 Q2	$751K	Buy	+20,300	New	+$766K	0.02%	328

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Goldman & Co's CLDX Position: Q4 2020 in Review

J. Goldman & Co sold out of Celldex Therapeutics (CLDX) in Q4 2020, closing a stake of 76,055 shares — an estimated $1.13M sold.

J. Goldman & Co first reported a position in CLDX in Q3 2020 and held it in 1 quarter. The position peaked at $1.13M in Q3 2020. 130 funds tracked by Wall St. Rank hold CLDX as of Q4 2020.

J. Goldman & Co reported no remaining Celldex Therapeutics position as of Q4 2020 after selling out during the quarter.
J. Goldman & Co sold 76,055 Celldex Therapeutics shares in Q4 2020, an estimated $1.13M.
J. Goldman & Co first reported a position in Celldex Therapeutics in Q3 2020 and held it in 1 quarter.
J. Goldman & Co's Celldex Therapeutics position peaked at $1.13M in Q3 2020.
130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2020.

Based on J. Goldman & Co's 13F filing for Q4 2020, filed 16 Feb 2021.